Clinical Trial

A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is a Phase II, multicenter, double-blind, randomized, parallel, placebo-controlled clinical trial designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of TQC2938 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It is anticipated that 256 subjects will be enrolled.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-17.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-04-01
Trial Details
NCT Number NCT06789289
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Chronic Obstructive Pulmonary Disease
Enrollment 256 participants
Start Date 2025-03-17
Primary Completion 2027-03-17 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-07